DETERMINATION OF IMIPENEM (N-FORMIMIDOYL THIENAMYCIN) IN HUMAN-PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, COMPARISON WITH MICROBIOLOGICAL METHODOLOGY AND STABILITY
DETERMINATION OF IMIPENEM (N-FORMIMIDOYL THIENAMYCIN) IN HUMAN-PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY, COMPARISON WITH MICROBIOLOGICAL METHODOLOGY AND STABILITY
复制标题
DOI:
10.1016/0378-4347(84)80069-9
复制
发表时间:
1984-01-01
期刊:
影响因子:
--
通讯作者:
BAYNE, WF
中科院分区:
文献类型:
--
作者:
GRAVALLESE, DA;MUSSON, DG;BAYNE, WF
High-performance liquid chromatographic (HPLC) methods using UV detection have been developed for the assay of the antibiotic imipenem (N-formimidoyl thienamycin) in human plasma and urine. A reversed-phase analytical column is employed in the plasma assay method and a cation-exchange column is used in the urine assay method. Both methods use borate buffer in the mobile phase. The method of preparation of human fluid samples for HPLC injection has been optimized with respect to the stability of imipenem in aqueous buffers, in morpholine buffer-ethylene glycol stabilizer and in urine and plasma. Preparation of the samples before injection into the HPLC systems involves deproteination/filtration of the plasma/urine samples. The open lactam metabolite and the coadministered dehydropeptidase inhibitor, cilastatin sodium, did not interfere with the 313-nm detection of imipenem in either the plasma or the urine assay. Thienamycin, the precursor of imipenem and an impurity in imipenem formulations, is separted from the drug using both of these methods. Concentrations generated from the HPLC analysis of plasma and urine samples from 2 healthy volunteers compared favorably with results using a microbiological assay method. Correlation of the 2 methods gives r .gtoreq. 0.990 for both fluids.